A Director at Biospecifics Technologies Corp is Exercising Options


Today it was reported that a Director at Biospecifics Technologies Corp (NASDAQ: BSTC), Michael Schamroth, exercised options to buy 15,000 BSTC shares at $20.00 a share, for a total transaction value of $300K. The options were close to expired and Michael Schamroth retained stocks.

Following this transaction Michael Schamroth’s holding in the company was increased by 17.86% to a total of $5 million. Following Michael Schamroth’s last BSTC Buy transaction on June 04, 2018, the stock climbed by 7.4%.

See today’s analyst top recommended stocks >>

Based on Biospecifics Technologies Corp’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $7.1 million and quarterly net profit of $4.3 million. In comparison, last year the company earned revenue of $6.54 million and had a net profit of $2.62 million. BSTC’s market cap is $365.7M and the company has a P/E ratio of 27.14. Currently, Biospecifics Technologies Corp has an average volume of 19.82K.

Starting in November 2017, BSTC received 9 Buy ratings in a row.

In the last 30 days, insiders have sold $6.81M worth of BSTC shares and purchased $1.35M worth of BSTC shares. The insider sentiment on Biospecifics Technologies Corp has been negative according to 11 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Michael Schamroth’s trades have generated a -0.5% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioSpecifics Technologies Corp. engages in the development of an injectable collagenase for multiple indications. Its products include XIAFLEX, which is a treatment used for Dupuytren’s contracture. The company was founded in 1990 and is headquartered in Lynbrook, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts